Loading
JY232 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for multiple myeloma.
JY232 is an in vivo CAR-T (an infusion that makes CAR-T cells inside the body) from Genocury Biotech. The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises. An investigator-initiated, single-centre early phase 1 study (NCT07336823), registered in January 2026, is recruiting. Whether it works in people has not been established.
The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises.
1.JY232 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JY232" OR ABSTRACT:"JY232" OR TITLE:"JY232 Injection" OR ABSTRACT:"JY232 Injection") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JY232, not a curated reading list.
Shares Genocury Biotech and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Genocury Biotech and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/